Valerie VanhoorenCEO at Ona TherapeuticsSpeaker
Valerie Vanhooren is the co-founder & CEO of ONA Therapeutics. At ONA Therapeutics, Valerie has spearheaded the development of first-in-class oncology therapeutics. Since co-founding ONA Therapeutics in 2019, the team has grown to over 20 members and secured over 30 million euros from a syndicate of international investors and public grants.
Previously, Valerie was head of research at ProteoDesign, a Princeton University spin-off currently known as SpliceBio, and project leader at Ablynx, a biologics company acquired by Sanofi engaged in the development of therapeutic Nanobodies®. At Ablynx, she led early-stage drug development projects in collaboration with multiple internationally operating pharmaceutical entities.
Valerie earned her doctorate at University of Ghent, Belgium, and carried out postdoctoral studies at the VIB-Ghent University. She has extensive expertise in immuno-oncology, inflammation and aging research and has published broadly in these fields.